English   español  
Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/94776
Share/Impact:
Statistics
logo share SHARE logo core CORE   Add this article to your Mendeley library MendeleyBASE

Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL
Exportar a otros formatos:

Title

Calmodulin levels in blood cells as a potential biomarker of Alzheimer's disease

AuthorsEsteras, Noemí ; Alquézar, Carolina ; De la Encarnación, Ana; Villarejo, Alberto; Bermejo-Pareja, Félix; Martín-Requero, Ángeles
Issue Date7-Nov-2013
CitationAlzheimer's Research & Therapy 5(6):55 (2013)
AbstractAbstract Introduction The clinical features of Alzheimer’s disease (AD) overlap with a number of other dementias and conclusive diagnosis is only achieved at autopsy. Accurate in-life diagnosis requires finding biomarkers suitable for early diagnosis, as well as for discrimination from other types of dementia. Mounting evidence suggests that AD-dependent processes may also affect peripheral cells. We previously reported that calmodulin (CaM) signaling is impaired in AD lymphoblasts. Here, we address the issue as to whether the assessment of CaM levels in peripheral cells could serve as a diagnostic biomarker. Methods A total of 165 subjects were enrolled in the study, including 56 AD patients, 15 patients with mild cognitive impairment, 7 with frontotemporal dementia associated with progranulin mutations, 4 with dementia with Lewy bodies, 20 patients with Parkinson’s disease, 10 with amyotrophic lateral sclerosis, 5 with progressive supranuclear palsy, and 48 cognitively normal individuals. CaM levels were then analyzed in lymphoblasts, peripheral blood mononuclear cells and plasma. Receiver operating characteristic (ROC) curve analyses were employed to evaluate the diagnostic performance of CaM content in identifying AD patients. Results Compared with control individuals, CaM levels were significantly increased in AD cells, but not in the other neurodegenerative disorders. CaM levels differentiated AD from control with a sensitivity of 0.89 and a specificity of 0.82 and were not dependent on disease severity or age. MCI patients also showed higher levels of the protein. Conclusions CaM levels could be considered a peripheral biomarker for AD in its early stage and help to discriminate from other types of dementia.
Publisher version (URL)http://dx.doi.org/10.1186/alzrt219
URIhttp://hdl.handle.net/10261/94776
DOI10.1186/alzrt219
E-ISSN1758-9193
Appears in Collections:(CIB) Artículos
Files in This Item:
File Description SizeFormat 
alzrt219.xml87,96 kBXMLView/Open
ALZRT219-S1.DOCX98,43 kBMicrosoft Word XMLView/Open
alzrt219.pdf786,21 kBAdobe PDFThumbnail
View/Open
Show full item record
Review this work
 

Related articles:


WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.